TESARO Summarizes TSR-042 Clinical Data Presented at AACR
16. April 2018 09:00 ET
|
TESARO, Inc.
Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers Data support unique and convenient dosing scheduleRegulatory...
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
27. April 2017 08:15 ET
|
TESARO, Inc.
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...